CHARLOTTETOWN, Prince Edward Island (PRWEB)
January 23, 2023

Pegasus Biotech has announced a major expansion to their Charlottetown, PE location, adding 1000 sqft of additional laboratory space. The added space will be used to expand their existing CL2 services, fermentation capabilities, and process development capabilities, and it enables the company to accelerate its progress toward the addition of GMP pilot scale production capability within the next 3 years.

“With the rapid growth we have experienced in the past two years, maintaining sufficient lab bench space has been an ongoing challenge for Pegasus. The additional laboratory space gives us room to maintain our aggressive pace of growth, and expansion of service offerings to the global human and animal health industry” said Dr. Yimy Mena, CEO of Pegasus Biotech. In the past 12 months Pegasus Biotech has more than doubled the number of scientists employed at its Charlottetown site in order to keep up with the high demand for both conventional and DNA vaccine development services from clients in North America, South America, Europe, Asia and the Middle East.

The mission of Pegasus Biotech is to enable their clients to bring cutting edge innovation to the global human and animal health markets. Their area of expertise is ensuring that client biopharmaceutical and vaccine development activities result in commercially viable products that are compliant with global regulations. Services include seed-to-formulation process development along with associated analytical development.

To learn more about Pegasus’ services, click here http://www.pegasusbio.com.

About Pegasus Biotech Inc: Pegasus Biotech Inc. is a full-service biotechnology contract research organization. They offer both process and analytical development services to the global pharma industry. They specialize in vaccine and biopharmaceutical development and are global leaders in DNA vaccine development.

Share article on social media or email: